Vokinger KN, Avorn J, Kesselheim AS. Sources of innovation in gene therapies - Approaches to achieving affordable prices. NEJM. 2023;388:202–95.

Kaji EH. Gene and stem cell therapies. JAMA. 2001;285:545.

Article  CAS  PubMed  Google Scholar 

Bender E. Regulating the gene-therapy revolution. Nature. 2018;564:S20–S22.

Article  CAS  PubMed  Google Scholar 

High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381:455–64.

Article  CAS  PubMed  Google Scholar 

Wang S, Sun F, Huang H, Chen K, Li Q-J, Zhang L, et al. The landscape of cell and gene therapies for solid tumors. Cancer Cell. 2021;39:7–8.

Article  PubMed  Google Scholar 

Bach PB, Giralt SA, Saltz LB. FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug. JAMA. 2017;318:1861.

Article  PubMed  Google Scholar 

Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78:834.

Article  PubMed  Google Scholar 

Bitetti I, Lanzara V, Margiotta G, Varone A Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study. Gene Ther. 2022. https://doi.org/10.1038/s41434-022-00341-6.

Ledford H. Gene therapy’s comeback: how scientists are trying to make it safer. Nature. 2022;606:443–4.

Article  CAS  PubMed  Google Scholar 

Editorial. Gene therapy needs a long-term approach. Nat Med. 2021;27:563–563.

Article  Google Scholar 

US Food and Drug Administration. Approved Cellular and Gene Therapy Products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products (accessed 12 January 2023).

European Medicines Agency. Medicines. https://www.ema.europa.eu/en/medicines (accessed 12 January, 2023).

Federal Joint Committee (G-BA). The benefit assessment of medicinal products in accordance with the German Social Code, Book Five (SGB V), section 35a. https://www.g-ba.de/english/benefitassessment/ (accessed 12 January, 2023).

Haute Autorité de Santé. https://www.has-sante.fr/jcms/fc_2876008/fr/medicament (accessed 12 January, 2023).

Swissmedic. Listen und Verzeichnisse. https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html (accessed 12 January, 2023).

Hwang TJ, Ross JS, Vokinger KN, Kesselheim AS. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ. 2020;371:m3434.

Article  PubMed  PubMed Central  Google Scholar 

Vokinger KN, Hwang TJ, Glaus CEG, Kesselheim AS. Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019. JAMA Netw Open. 2022;5:e226479.

Article  PubMed  PubMed Central  Google Scholar 

Vokinger KN, Kesselheim AS, Glaus CEG, Hwang TJ. Therapeutic value of drugs granted accelerated approval or conditional marketing authorization in the US and Europe From 2007 to 2021. JAMA Health Forum. 2022;3:e222685.

Article  PubMed  PubMed Central  Google Scholar 

Gene therapies should be for all. Nat Med. 2021; 27: 1311–1311.

Newham M, Vokinger KN Adverse effects of acquisitions in the pharmaceutical industry. Nat Med. 2022. https://doi.org/10.1038/s41591-022-01784-5.

Gene therapy for spinal muscular atrophy: the benefit–cost profile. eClinicalMedicine 2021; 37: 101065.

Garrison LP, Jiao B, Dabbous O. Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies. J Manag Care Spec Pharm. 2021;27:674–81.

PubMed  Google Scholar 

Salcedo J, Bulovic J, Young CM. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease. Sci Rep. 2021;11:10838.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vokinger KN, Hwang TJ, Daniore P, Lee CC, Tibau A, Grischott T, et al. Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe. JAMA Oncol. 2021;7:e212026.

Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis. Lancet Oncol. 2020;21:664–70.

Article  CAS  PubMed  Google Scholar 

Vokinger KN, Naci H. Negotiating drug prices in the US—Lessons From Europe. JAMA Health Forum. 2022;3:e224801.

Article  PubMed  Google Scholar 

Pagliarulo N Bluebird to withdraw gene therapy from Germany after dispute over price. Biopharmadive 2021. https://www.biopharmadive.com/news/bluebird-withdraw-zynteglo-germany-price/598689/ (accessed 12 January 2023).

Wissensschau.de. Gybera - die erste Gentherapie fand nur eine Patientin 2021. https://www.wissensschau.de/genom/gentherapie_glybera_lipoproteinlipase-defizienz.php (accessed 12 January 2023).

Businesswire. bluebird bio reports second quarter financial results and provides operational update 2021. https://www.businesswire.com/news/home/20210809005334/en/bluebird-bio-Reports-Second-Quarter-Financial-Results-and-Provides-Operational-Update (accessed 12 January 2023).

Kashoki M, Hanaizi Z, Yordanova S, Veselý R, Bouygues C, Llinares J, et al. A comparison of EMA and FDA decisions for new drug marketing applications 2014–2016: concordance, discordance, and why. Clin Pharmacol Ther. 2020;107:195–202.

Article  PubMed  Google Scholar 

Trotta F, Leufkens HGM, Schellens JHM, Laing R, Tafuri G. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. J Clin Oncol. 2011;29:2266–72.

Article  PubMed  Google Scholar